News & Updates
Filter by Specialty:
Oncoplastic surgery boosts quality of life in breast cancer patients
In women with breast cancer, oncoplastic surgery improves quality of life and is associated with high patient satisfaction, reports a new study.
Oncoplastic surgery boosts quality of life in breast cancer patients
04 May 2022Statins confer some protection against breast cancer recurrence in Asians
Taking a statin after breast cancer surgery appears to reduce the risk of disease recurrence in Asians, especially among those with invasive cancers, as shown in a study from Singapore.
Statins confer some protection against breast cancer recurrence in Asians
04 May 2022New HF guideline: Quad therapy, HFmrEF, and more
Hot on the heels of ACC.22 ground-breaking reports, the ACC/AHA/HFSA* released the 2022 heart failure (HF) guideline, with special emphasis on quad therapy for patients with reduced ejection fraction.
New HF guideline: Quad therapy, HFmrEF, and more
04 May 2022Brigatinib a potential standard treatment alternative for treatment-naive ALK+ NSCLC
In patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer (ALK+ NSCLC) who were ALK inhibitor-naïve, brigatinib showed superior efficacy and safety over crizotinib, according to the final results of the phase III ALTA-1L* trial presented at ELCC 2022.
Brigatinib a potential standard treatment alternative for treatment-naive ALK+ NSCLC
30 Apr 2022Secondary OPINION analysis boosts safety profile of maintenance olaparib for ovarian cancer
In women with platinum-sensitive relapsed ovarian cancer without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (non-gBRCAm), maintenance olaparib was well tolerated, according to the secondary safety results from the phase IIIb OPINION study presented at SGO 2022.
Secondary OPINION analysis boosts safety profile of maintenance olaparib for ovarian cancer
29 Apr 2022Intensified systemic therapy with ADT improves outcomes in high-risk prostate cancer
In patients with high-risk or unfavourable nonmetastatic prostate cancer (nmPC) receiving local definite therapy, the intensification of systemic therapy using chemotherapy or an androgen receptor signaling inhibitor (ARSI), in combination with androgen deprivation therapy (ADT), leads to better oncologic survival measures, reports a recent meta-analysis.